Health Minister announces a $7 million grant to Magellan Stem Cells

Last night on 10 News First (see the news report here), the Australian Government’s Health Minister The Hon Mark Butler announced a $7 million grant to Magellan Stem Cells to help deliver a Phase III human trial for our donor stem cell treatment for osteoarthritis. The minister said: “Osteoarthritis is a huge cause of pain […]

Magellan Update August 2024

From the Chair Magellan Continues to progress its operational and strategic plans. With a focus on a successful laboratory licensing process for the TGA, publication of the results of the Phase 1/2 trial, preparation for the Phase 3 trial in 2025 and ongoing planning for eventual manufacture of cells for our trial and others our […]

Magellan Update April 2024

AGM AND TOUR OF FACILITY The Magellan Stem Cells Annual General Meeting of was held in December at the Braeside premises where Magellan Chair, Lou Panaccio conducted a fruitful meeting for those in attendance and those online. Several investors joined us after the meeting for a tour of the impressive new facility which was well […]

Magellan Update October 2023

GMP LAB CONSTRUCTION COMPLETED Magellan has completed the construction of the GMP laboratory facility, with the emphasis now on balancing and testing systems. The installation of the Environmental Monitoring System (EMS) is largely complete. The research and development lab is being used to evaluate Bioreactor manufacturing methods and donor cells culturing, with a range of tests […]

Magellan Update July 2023

MAGELLAN APPOINTS NEW SHARE REGISTRY Magellan is pleased to announce that we have appointed Bio101 – a leading provider of financial, accounting, and company secretarial services to the biotechnology and life sciences sector – to provide our new secure share registry office service. The registry will hold details of members’ shareholdings as well as a library […]

Magellan Update April 2023

BUILDERS ON SITE AT NEW LABS. The building process for Magellan’s new laboratories at Braeside has commenced. The development will include two GMP (Good Manufacturing Practice) laboratories. The factory/office complex is already complete and construction of Magellan laboratories has commenced. The first lab to be completed will be the Research and Development laboratory which will enable Magellan […]

Magellan are pleased to announce the results of our Phase 1/2 allogenic trial. The research findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI), which publishes the evidence-based, international consensus guidelines on osteoarthritis management.  

Australian Health Minister announced a $7 million grant to Magellan Stem Cells – read more here

Should you want further information regarding our results or media release please email info@magellanstemcells.com.au or call 03 9270 8080.

Investment Enquiry

Download the full Investor Presentation